Eliquis FDA Approval History
FDA Approved: Yes (First approved December 28, 2012)
Brand name: Eliquis
Generic name: apixaban
Dosage form: Tablets and Tablets for Oral Suspension
Company: Bristol-Myers Squibb Company
Treatment for: Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis, Deep Vein Thrombosis, Prophylaxis, Pulmonary Embolism, Thromboembolic Stroke Prophylaxis, Venous Thromboembolism
Eliquis (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial therapy.
- Eliquis is indicated:
- to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.
- for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery.
- for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy.
- for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.
Development timeline for Eliquis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.